Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial (Q47412133)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 November 2017

Language	Label	Description	Also known as
English	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial	scientific article published on 9 November 2017

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

quality of life

1 reference

based on heuristic

inferred from title

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Julie R Brahmer

1

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Delvys Rodríguez-Abreu

2

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Andrew G Robinson

3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Rina Hui

4

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Tibor Csőszi

5

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Andrea Fülöp

6

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Maya Gottfried

7

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Nir Peled

8

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Ali Tafreshi

9

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Sinead Cuffe

10

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Mary O'Brien

11

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Suman Rao

12

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Katsuyuki Hotta

13

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Jin Zhang

14

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Gregory M Lubiniecki

15

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Anne C Deitz

16

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Reshma Rangwala

17

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Martin Reck

18

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

publication date

9 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

18

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

12

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

1600-1609

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom burden and quality of life in advanced non-small cell lung cancer patients in France and Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptoms in adults with lung cancer. A systematic research review

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Testing the EORTC Quality of Life Questionnaire on cancer patients with heterogeneous diagnoses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930690-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30690-3

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 January 2018

http://europepmc.org/abstract/MED/29129441

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47412133&oldid=2155731708"